|
Name |
Asperolide B
|
Molecular Formula | C16H16O5 | |
IUPAC Name* |
(1S,9R,12R,13R,15S,17R)-1,12-dimethyl-5,10,14-trioxapentacyclo[7.7.1.02,7.012,17.013,15]heptadeca-2,7-diene-4,11-dione
|
|
SMILES |
C[C@]12C[C@H]3[C@H](O3)[C@]4([C@@H]1[C@@H](C=C5C2=CC(=O)OC5)OC4=O)C
|
|
InChI |
InChI=1S/C16H16O5/c1-15-5-10-13(20-10)16(2)12(15)9(21-14(16)18)3-7-6-19-11(17)4-8(7)15/h3-4,9-10,12-13H,5-6H2,1-2H3/t9-,10+,12-,13+,15-,16-/m1/s1
|
|
InChIKey |
YESVFYJUFXNDLO-AZPXEMHPSA-N
|
|
Synonyms |
Asperolide B
|
|
CAS | NA | |
PubChem CID | 57331841 | |
ChEMBL ID | CHEMBL2011692 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 288.29 | ALogp: | 0.5 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.1 | Aromatic Rings: | 5 |
Heavy Atoms: | 21 | QED Weighted: | 0.5 |
Caco-2 Permeability: | -5.303 | MDCK Permeability: | 0.00002470 |
Pgp-inhibitor: | 0.959 | Pgp-substrate: | 0.094 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.998 |
30% Bioavailability (F30%): | 0.916 |
Blood-Brain-Barrier Penetration (BBB): | 0.897 | Plasma Protein Binding (PPB): | 58.89% |
Volume Distribution (VD): | 0.539 | Fu: | 60.87% |
CYP1A2-inhibitor: | 0.038 | CYP1A2-substrate: | 0.36 |
CYP2C19-inhibitor: | 0.026 | CYP2C19-substrate: | 0.704 |
CYP2C9-inhibitor: | 0.024 | CYP2C9-substrate: | 0.034 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.051 |
CYP3A4-inhibitor: | 0.158 | CYP3A4-substrate: | 0.667 |
Clearance (CL): | 13.255 | Half-life (T1/2): | 0.845 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.091 |
Drug-inuced Liver Injury (DILI): | 0.581 | AMES Toxicity: | 0.513 |
Rat Oral Acute Toxicity: | 0.864 | Maximum Recommended Daily Dose: | 0.791 |
Skin Sensitization: | 0.948 | Carcinogencity: | 0.657 |
Eye Corrosion: | 0.968 | Eye Irritation: | 0.915 |
Respiratory Toxicity: | 0.942 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002903 | 0.648 | D0G6AB | 0.274 | ||||
ENC000924 | 0.644 | D0D2VS | 0.250 | ||||
ENC001928 | 0.597 | D0K7LU | 0.241 | ||||
ENC005203 | 0.597 | D06AEO | 0.226 | ||||
ENC002394 | 0.597 | D0C7JF | 0.222 | ||||
ENC002850 | 0.560 | D04GJN | 0.221 | ||||
ENC003795 | 0.345 | D0G8BV | 0.218 | ||||
ENC003927 | 0.340 | D0A2AJ | 0.211 | ||||
ENC003323 | 0.322 | D0F1UL | 0.206 | ||||
ENC002931 | 0.318 | D0Z4ZT | 0.204 |